Business Wire

Eaton to showcase comprehensive commercial vehicle clutch portfolio at Automechanika Frankfurt

5.9.2024 12:30:00 CEST | Business Wire | Press release

Share

Intelligent power management company Eaton today announced it is showcasing an array of aftermarket clutch solutions for the Europe, Middle East and Africa (EMEA) markets at Automechanika Frankfurt in Hall 3, booth D11. Eaton is displaying its complete line of angle spring clutches, diaphragm spring clutches, concentric pneumatic clutch actuators and ServiceRanger diagnostic solutions for commercial vehicles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905507731/en/

Eaton’s Advantage series automated diaphragm spring clutches are designed for all makes and models of automated manual transmissions (AMT) in the EMEA market. (Photo: Business Wire)

“We are dedicated to expanding our product portfolio to meet the changing needs of the global market and increasing customer relationships in all market channels,” said Tim Bauer, vice president, Aftermarket, Eaton’s Mobility Group.

The angle spring clutches are used for manual transmissions and are offered in two series. The Advantage series features strap drive technology that improves intermediate plate connection for more reliable performance while eliminating lug rattle and fatigue. Additionally, they are designed with a dual-seal release bearing, which allows for best-in-class 80,000-km lube intervals, reducing maintenance downtime. Eaton also offers the EverTough® series, which provides a more cost-effective solution for vehicles older than seven years.

Eaton also will be displaying its Advantage series automated diaphragm spring clutches for all makes and models of automated manual transmissions (AMT) in the EMEA market. These clutches are built to strict OEM quality standards and minimize idling noise while reducing severe vibrations and delivering outstanding performance and extended clutch life.

Eaton will also be showing its electronic clutch actuator that is designed for its UltraShift Plus transmission along with its concentric pneumatic clutch actuators (CPCAs) for DT12®, the Volvo I-Shift and Mack mDRIVE AMTs. The CPCAs help optimize vehicle performance by working with a vehicle’s AMT to continuously determine the ideal release position and clutch actuation when the transmission shifts. Many current AMT-equipped trucks are no longer under factory warranty, so fleet customers need reliable parts to complete repairs and maintenance. Replacing the CPCA during clutch service can help save repair time and cost while reducing downtime for unscheduled maintenance.

To support AMTs operating in the market Eaton offers its ServiceRanger 4 Pro Plus (SR4 Pro Plus) software. This diagnostic software and service tool is designed to support all Eaton AMTs, hybrid powertrain systems, Advantage Automated Series clutches and Eaton Cummins Automated Transmission Technologies. In addition, there is an “App Center” that allows users to calibrate all makes and models of diaphragm spring clutches and CPCAs that fit DT12®, Volvo® I-Shift and Mack mDRIVE AMTs.

“Eaton now offers a complete line of aftermarket clutch products in EMEA for all makes and models of trucks. Whether the truck is one year old or over fifteen years old, we have the clutch portfolio to provide our customers with cost effective solutions to keep their vehicle operating,” said Pawel Kepka, director, Aftermarket EMEA, Eaton’s Mobility Group.

Learn more about Eaton’s aftermarket solutions.

Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.

Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905507731/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye